Naproxen is NOT appropriate for treating central fever in adults
Central fever (non-infectious fever from neurologic injury) should not be routinely treated with antipyretics, including naproxen, as current critical care guidelines recommend against routine antipyretic use for temperature reduction in critically ill patients with fever 1. The 2023 Society of Critical Care Medicine/IDSA guidelines specifically suggest avoiding routine antipyretic medications for the specific purpose of reducing temperature in critically ill patients with fever 1.
Key Distinction: Central Fever vs. Neoplastic Fever
The evidence you may find regarding naproxen's effectiveness applies to neoplastic fever (tumor-related fever), not central fever (neurogenic hyperthermia from brain injury). These are completely different entities:
- Central fever results from hypothalamic dysfunction after neurologic injury (stroke, trauma, surgery)
- Neoplastic fever results from cytokine release by malignant tumors
While naproxen shows a 94.1% success rate for neoplastic fever 2 and has been effective in multiple studies for tumor-related fever 3, 4, this evidence does not translate to central fever management.
Why Antipyretics Generally Fail in Central Fever
Central fever occurs when the hypothalamic thermoregulatory center is damaged or dysfunctional. Since NSAIDs like naproxen work by inhibiting prostaglandin synthesis in the hypothalamus 5, they are ineffective when the hypothalamus itself is the problem. The mechanism of action fundamentally doesn't address the underlying pathophysiology.
When Antipyretics May Be Considered
The 2023 guidelines do suggest using antipyretics (over non-pharmacologic methods) only when patients value comfort by reducing temperature 1. However, this is a weak recommendation with low-quality evidence and applies to general ICU fever, not specifically central fever.
If Naproxen Were to Be Used (Not Recommended)
Should you decide to use naproxen despite the lack of supporting evidence for central fever:
- Standard dosing: 250-500 mg twice daily 5
- Use lowest effective dose for shortest duration 5
- Onset: Pain relief begins within 1 hour; peak plasma levels at 2-4 hours 5
Critical Precautions
- Avoid in renal impairment (CrCl <30 mL/min) - naproxen is contraindicated 5
- Avoid in patients on anticoagulants - increases bleeding risk significantly 6
- Monitor for GI complications - 10-20% experience dyspepsia; serious GI bleeding risk increases with age (1 in 235 for adults >65 years) 6
- Reduce dose in elderly - increased unbound drug fraction despite normal total levels 5
- Avoid in CHF, cirrhosis, or preexisting renal disease - risk of acute renal failure 6
Better Alternatives for Central Fever
For true central fever, consider:
- External cooling measures (cooling blankets, ice packs)
- Bromocriptine or dantrolene in refractory cases
- Addressing the underlying neurologic injury
The guideline preference for comfort-driven antipyretic use 1 suggests that if temperature reduction is truly needed for patient comfort (not for temperature control itself), any standard antipyretic would be reasonable, but naproxen offers no specific advantage over acetaminophen or ibuprofen for this indication.